Literature DB >> 28456365

Medication management after intramedullary nailing of atypical fractures.

Jean-Marc Feron1, Adeline Cambon-Binder2.   

Abstract

Long term use of bisphosphonates (BPs) in osteoporotic patients may be associated with stress fractures of the sub-trochanteric and shaft area of the femur, so called "atypical" femoral fractures (AFF). Specific diagnosis criteria have been defined with 5 major features; the presence of four of them characterizes the AFF. Once a complete fracture occurred, the best surgical treatment is closed reduction and intra medullary nailing. The BPs treatment should be stopped immediately after an AFF occurred. Dietary calcium and vitamin D status should be assessed, and adequate supplementation prescribed. Principle of combination of a systematic bone anabolic treatment is strongly debated. The recombinant parathyroid hormone 1-34 or Teriparatide ® (TPTD) has an anabolic effect on bone and prevent osteoporotic fractures. Available preclinical and clinical data have also demonstrated the role played by TPTD to enhance bone fracture healing and the potential beneficial effect in impaired fracture healing or specific clinical condition like AFFs. Some authors have proposed in incomplete BP use stress fractures different medical management according the MRI findings. Bone anabolic agents may be promising both to prevent healing complications in AFFs and to promote healing in conservative treatment of incomplete AFFs. More clinical studies are needed to confirm this hypothesis.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atypical femoral fracture; Bisphosphonates; Fatigue fracture; Osteoporosis; PTH

Mesh:

Substances:

Year:  2017        PMID: 28456365     DOI: 10.1016/j.injury.2017.04.030

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  1 in total

1.  [Atypical distal tibial shaft fractures in a patient with bilateral TKA and antiresorptive treatment].

Authors:  R Schimpf; H Siekmann; C Bauer; F Radetzki
Journal:  Orthopade       Date:  2018-08       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.